Navigation Links
Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Date:7/7/2011

inal tract (29%), allergic rhinitis (29%), acne-like skin inflammation (25%), pharyngitis or inflammation of the pharynx (25%), vomiting (25%), abnormal behavior (21%), cough (21%), dry skin (21%), scratching of the skin (21%), external ear infection (21%) and skin infection (21%). The most common Grade 3 AEs (with an incidence of at least 5%) were stomatitis or mouth sores, convulsion and decreased neutrophil count. In addition, single cases of Grade 3 sinusitis, pneumonia, viral bronchitis, gastroenteritis or inflammation of the gastrointestinal tract, limb abscess, aspiration, cyclic neutropenia, post lumbar puncture syndrome, sleep apnea syndrome and dizziness were reported. A single case of Grade 4 convulsion was reported. Adverse events were mostly Grade 1 (mild) or Grade 2 (moderate) in severity and were consistent with those previously reported at six months(11).

About everolimusIn the US, Afinitor® (everolimus) tablets is approved to treat patients with SEGA associated with TS who require therapeutic intervention but are not candidates for curative surgical resection. The effectiveness of everolimus is based on an analysis of change in SEGA volume. Clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been shown. Everolimus is approved in Switzerland as Votubia® (everolimus) tablets for the treatment of patients three years of age and older, with SEGA associated with TS, for whom surgery is not a suitable option. Should everolimus be approved in the EU, the trade name will be Votubia.

Afinitor is approved in the US and Switzerland for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib and also in the EU for the treatment of patients with advanced RCC whose disease has progressed on or after treatment with vascular endothelial growth factor (VEGF)-targeted therapy.

Afinitor is approved in the US f
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia
2. GlaxoSmithKline Implements Next Phase of New Incentive Compensation Program for U.S. Sales Representatives
3. Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal
4. Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain
5. Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
6. DNA Medicine Institute Awarded Two Phase III SBIR NASA Contracts for Its rHEALTH Sensor
7. Phase I of the Swedish/Issaquah Medical Center Campus to Open in July
8. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
9. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
10. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
11. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Corporation , a neurodiagnostics medical device company based in ... Forcht Dagi , MD, DmedSc, MPH, MBA, FACS, FRCSEd  was ... " Teo Forcht Dagi is an experienced leader with ... said Remis Bistras , President and CEO of Vittamed. ... entrepreneurial expertise to our Board." Dr. Dagi is ...
(Date:8/29/2014)... , Aug. 29, 2014 Diseases largely eradicated ... generation ago are returning. Measles was declared eliminated in ... 2014 as of August 15—the highest incidence in 20 ... health department declared whooping cough a problem of ... getting sick and dying from these preventable diseases—in part ...
(Date:8/29/2014)... -- ChemImage will present a workshop focused on hyperspectral ... Science Society,s 22 nd International Symposium on ... .  Forensic Scientists will be in attendance ... can bring to examination procedures. ... Development at ChemImage, will host a workshop during ...
Breaking Medicine Technology:Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
... The Department of Justice, on behalf of the U.S. Food ... permanent injunction against generic drug manufacturer Ranbaxy in the ... filed against Ranbaxy Laboratories, Ltd., an Indian corporation; its ... Dale Adkisson, senior vice president, head of global quality, ...
... Fine Chemicals LLC (AFC), a wholly owned subsidiary of ... today that is has been granted Registration as a ... Agency (DEA). AFC has been involved in ... under a Researcher,s License from the DEA.  Recent facilities ...
Cached Medicine Technology:Department of Justice files consent decree of permanent injunction against Ranbaxy 2Department of Justice files consent decree of permanent injunction against Ranbaxy 3Department of Justice files consent decree of permanent injunction against Ranbaxy 4AMPAC Fine Chemicals Expands Into Controlled Substance Manufacturing 2AMPAC Fine Chemicals Expands Into Controlled Substance Manufacturing 3AMPAC Fine Chemicals Expands Into Controlled Substance Manufacturing 4
(Date:8/30/2014)... (PRWEB) August 30, 2014 One of the ... era is the gluten-free diet. Originally meant for sufferers of ... a catchall for people who are looking to get healthier ... not only is this kind of information erroneous, it also ... problems because of a drastic change in their food ...
(Date:8/30/2014)... 30, 2014 LiveStreamingFitness.com, a company dedicated to ... healthy lifestyle resources, is proud to announce it has been ... at home fitness solutions by ABC’s Good Morning America. ... on ABC’s Good Morning America, “Live Streaming Fitness is the ... your day by streamlining your workout…to boot camp at Life ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 “In 2013, a ... The Jones Firm says in a recently released article on ... person was injured in an auto accident every 12 minutes, ... minutes,” they continue. “Based on the 2013 statistics, between now ... vehicle collision.” , The threat of an auto accident is ...
(Date:8/30/2014)... Boston, MA (PRWEB) August 30, 2014 ... and nurse practitioner locum tenens company , announces ... open September 1, 2014. Barton Associates is headquartered in ... Enfield, CT; Keene, NH; and Jupiter, FL. ... response to the increasing demand for healthcare providers. The ...
(Date:8/30/2014)... The first multidisciplinary recommendations on the management of ... are published today in EP Europace . ... the European Heart Rhythm Association (EHRA), the Acute ... of Percutaneous Cardiovascular Interventions (EAPCI), all of the ... of the task force, said: "Sudden cardiac death ...
Breaking Medicine News(10 mins):Health News:“What is Gluten: Three Things You Need to Know Before Adopting a Gluten-Free Diet” Reveals What Readers Need to Know About the Benefits of a Strict Gluten Diet - Vinamy 2Health News:LiveStreamingFitness.com is New Trend In Fitness 2Health News:Startling Washington Auto Accident Statistics Discussed In Recently Released Article By The Jones Firm 2Health News:Barton Associates Announces New Office Location in Austin, TX 2Health News:First multidisciplinary recommendations on management of arrhythmias in ACS patients 2
... blood clot that develops deep in the vein. It can ... ,People who require prolonged bed rest are vulnerable ... patients in intensive care and patient on catheters are at ... in critically ill patients , a small pulmonary embolism, which ...
... high levels of amino acid are associated with an ... been // associated with an increased risk of heart ... to be associated with homocystinuria, a rare disease characterized ... high levels have also been found to be associated ...
... consisting of periods of growth (anagen), regression (catagen), ... activation of ?-catenin in // telogen-phase adult hair ... Scientists have discovered that the transient activation of ... growth. ,Previous work has implicated Wnt/?-catenin ...
... Not all vitamins may be good for you. A new ... antioxidant vitamins, such as // E, C and beta carotene, ... ,Some studies have shown that vitamin E prevented the ... cells. Thus, the liver destroyed fewer of the bad lipoproteins. ...
... new type of stent that releases medication appears safe ... heart disease patients, // a process known as restenosis. ... drug everolimus. The drug acts by inhibiting cell reproduction ... similar drug-eluting stents, the one used in this study ...
... a recent study neurosurgeons say they are now convinced ... ,Studies in the past have suggested wearing helmets during ... the risk of skull base and cervical-spine (or neck) ... findings prompted researchers to study whether helmets harm or ...
Cached Medicine News:Health News:New Hair in 15 Days Could Now Be A Possibility Say Researchers 2
... contains primers and a FAM-labeled probe that ... gene. In addition, this ASR contains primers, ... internal control sequence. This ASR requires an ... Red reporter dyes such as the Cepheid ...
...
Reptilase-Time from Bothrops atrox...
Thrombin Activatable Fibrinolysis Inhibitor Assay Kit...
Medicine Products: